梯瓦制药美国公司的争议事件

来源摘录

• The lawsuit claims that Teva paid two third-party foundations more than $300 million to cover Medicare co-payment obligations of Copaxone patients.

• According to the lawsuit, Teva Pharmaceuticals USA Inc. and Teva Neuroscience Inc. illegally paid the Medicare co-pays for their multiple sclerosis product, Copaxone, through purportedly independent foundations that the companies used as conduits in violation of the Anti-Kickback Statute.

• Teva Pharmaceutical Industries Ltd. (TEVA) has been sued by the U.S. Department of Justice under the Federal False Claims Act.

来源摘录

• At the District Court of Delaware on Tuesday, Astellas Pharma Inc. (API), Astellas Ireland Co. Ltd. (AICL), and Astellas Pharma Global Development (APGD) filed a complaint against 21 pharmaceutical companies alleging patent infringement.

• The defendants are as follows: Sandoz Inc., Actavis Elizabeth LLC, Actavis LLC, Teva Pharmaceuticals USA Inc., Apotex Inc., Apotex Corp., Aurobindo Pharma Ltd., Aurobindo Pharma USA Inc., Aurolife Pharma LLC, Sawai Pharmaceutical Co. Ltd., Sawai USA Inc., Prinston Pharmaceutical Inc., Zhejiang Huahai Pharmaceutical Co. Ltd., Huahai US Inc., Solco Healthcare US LLC, Windlas Healthcare Pvt. Ltd., Windlas Biotech Ltd., Zydus Pharmaceuticals (USA) Inc., Cadila Healthcare Ltd. (doing business as Zydus Cadila), Lupin Ltd., and Lupin Pharmaceuticals, Inc.

• The patent in question, deemed the ’780 patent, corresponds to APGD’s Myrbetriq extended-release tablets, containing active ingredient mirabegron, which is used to treat overactive bladder.

来源摘录

• Mark Herring filed a lawsuit Thursday against Teva Pharmaceuticals USA, saying it and a company that it bought misrepresented the benefits and risks of products that include fentanyl.